Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lipodystrophy: early-phase trial registry
2 of 12 indexed Lipodystrophy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 2 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Lipodystrophy: 12 US clinical trials tracked, 2 recruiting.
Lipodystrophy is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), running 6 of these trials.
Enrollment posture brief
Registry condition lipodystrophy
OPEN 2 | RECR 17% | LATE 1 | EARLY 5 | RANK #1429 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Lipodystrophy lists 2 open slots (17% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lipodystrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lipodystrophy is recruiting below its size-band peers.
2 of 12 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Lipodystrophy research.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) accounts for 6 of 12 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Lipodystrophy trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 12 trials that report a genuine target (sentinel values excluded). 8 of those (66.7%) plan for fewer than 100 participants.
-
Lipodystrophy splits between interventional and observational designs.
8 interventional and 4 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT05419037
Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT05996536
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02262806
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02262832
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00069004
Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00021463
Lipodystrophy Connect Patient Registry
PatientCrossroads
NCT02577952
Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00028314
Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00119379
Exercise and Pioglitazone for HIV-Metabolic Syndromes
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00639457
Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
Topokine Therapeutics
NCT02647853
Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02639286
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lipodystrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lipodystrophy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lipodystrophy page
12 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Lipodystrophy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors the most Lipodystrophy trials on record, review their full trial history before evaluating a specific study. See National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lipodystrophy condition card totals 12 registered trials; most-linked intervention Abacavir sulfate; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.